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Methodology

Introduction
•
•

•
•

•

•

Von Willebrand disease (VWD) is an autosomal inherited
bleeding disorder.
The VWF is a multimeric plasma glycoprotein that binds to
platelets in order to deliver factor VIII, another essential
blood clotting protein, to sites in which vascular injury has
occurred.[2,4]
Three types include: Type 1 (partial deficiency), Type 2
(qualitative deficiency), and Type 3 (complete deficiency).
Type 1, the mild case, makes up 65% to 80% of cases; type
2, the moderate and qualitatively abnormal case of VWD,
makes up 20% to 35% of cases; with type 3, the severe
case, affecting 1 in 1 million people.[5]
Variations in Type 2 include: defects in multimerization
(type 2A), spontaneous platelet binding (type 2B), defects
in ligand binding with multimers (type 2M) and defects in
factor VIII binding (type 2N).
Next-Generation Sequencing has shown promise in its
diagnostic application but has not yet been implemented
for small-scale patient diagnostics.[1]

Patient Population and Blood Sampling
• Willing patients who have previously been diagnosed
with VWD
• ~4mL of blood will be used from each patient

Amplification and Sequencing
• Oligonucleotides will be used for amplification of
exons
• Multiplex PCRs will be used for amplification of the
VWF
• Each amplicon will be processed and analyzed
• A MiSeq platform will be used for sequence analysis[1]

Sequence Analysis
• NGS will be used for identification of specific variants,
further confirmed via Sanger sequencing
• Categorization of the disease according to type will be
recorded

VWF Structure & Function

Potential Conclusions
• NGS could provide viable results that could advocate for a
transition towards a clinically applied system of genetic
screening for patients with intermediate forms of VWD
• Identifying new variants among the three types of VWD,
through the continued use of gene sequencing for the VWF,
could broaden the diagnostic spectrum of VWD, to which
clinicians refer.

Potential Pitfalls

Figure 2: von Willebrand Factor is a multimeric oligomer that exists in multiple domains. Domain A2 is
shown and is said to be unprotected from unfolding via disulfide bonds.[3]

• Providing necessary tools in order to reduce costs of smallscale genetic testing for patients in a clinical setting could
present limitations in the effort for implementation for this
diagnostic modality
• Further specification for warranting such a diagnostic tool
would require additional evaluations
Figure 1: The visualization of von Willebrand factor in the formation of a clot for the coagulation
cascade.[4]

Specific Aims
• By first identifying the challenges clinicians face when
determining the proper diagnosis of a VWD patient, this
study aims to seek an improvement in diagnostic techniques,
by implementing the clinical use of genetic testing.
• More specifically, this study aims to improve the total
diagnostic time for the intermediate forms of VWD, through
the clinical application of Next-Generation Sequencing.
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